# Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

> **NCT00005852** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Chronic Myeloproliferative Disorders
- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** muromonab-CD3
- **DRUG:** cyclophosphamide
- **DRUG:** cyclosporine
- **DRUG:** methylprednisolone
- **PROCEDURE:** allogeneic bone marrow transplantation

## Key facts

- **NCT ID:** NCT00005852
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-06
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** — (—)
- **Why stopped:** low accrual
- **Last updated:** 2012-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005852, "Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*